Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Boardroom

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

Choices, choices: the rapidly evolving HIV treatment landscape

The treatment options for HIV in Europe has seen some revolutionary changes

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

US lawmaker pushes for drug price transparency

If passed a new Bill would demand pharma show how product price tags are worked out

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

Roche Basel Switzerland

Roche taps Qualcomm for remote health monitoring

Builds on collaboration with Novartis on remote trial observation

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

Gilead Sciences

Gilead agrees price cut for Sovaldi in Germany

Same sum as agreed with French government last November

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links